Dr. Sara Bouberhan, MD

Dr. Bouberhan practices at Massachusetts General Hospital in Boston, Massachusetts, part of Mass General Brigham.

Dr. Bouberhan's NPI, 1487929634, was assigned on March 20, 2012. Dr. Bouberhan graduated from University of Virginia School of Medicine in 2012. Dr. Bouberhan holds Massachusetts license 266674.

Dr. Bouberhan's primary practice is Massachusetts General Hospital, at 55 Fruit Street, Boston, MA 02114 in Suffolk County. The practice phone is (617) 726-2000.

Dr. Bouberhan's primary practice is Massachusetts General Hospital in Boston, Massachusetts, part of Mass General Brigham. Dr. Bouberhan is also affiliated with Brigham and Women's Hospital. The medical group on file is Massachusetts General Hospital. Dmand AI also links Dr. Bouberhan to 5 more hospitals, 4 medical groups, 1 community health center, 1 home health agency and 1 hospice, each named with a free account. Dr. Bouberhan's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bouberhan practices, 10 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Bouberhan's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Bouberhan is licensed in Massachusetts.

CMS data shows 1,378 Medicare services from Dr. Bouberhan across 6 procedure codes in 2024, for 170 Medicare patients. Medicare paid $97,735 for them.

CMS counts 170 Medicare patients who saw Dr. Bouberhan in 2024. The largest group is 65 to 74, with 76 patients. 72% of them have high blood pressure, and 67% have high cholesterol. 14% are also on Medicaid. Their average risk score is 2.42, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Bouberhan's median patient age at 74, with 97% women.

In 2024, Dr. Bouberhan wrote 617 Medicare Part D claims for 104 patients. 81% of them were for generic drugs. CMS names the drug for 446 of them, across 15 drugs with 11 or more claims each, at $572,267 in total drug cost. In 2023, CMS named 439 claims across 14 drugs.

Dr. Bouberhan accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Bouberhan as offering telehealth.

Dmand AI links 23 papers to Dr. Bouberhan, published from 2016 to 2025. 2019 was the busiest year, with 4. The most frequent topics are Ovarian Neoplasms, Endometrial Neoplasms and Antineoplastic Combined Chemotherapy Protocols. Dr. Bouberhan has published most often in J Clin Oncol. Dr. Bouberhan's most frequent co-authors are Cesar M. Castro, MD, MS, Stephen A. Cannistra, MD and Panagiotis Konstantinopoulos, MD.

Dmand AI links Dr. Bouberhan to 4 clinical trials. 3 are still active or recruiting. Conditions studied include Fallopian Tube Diseases, Endometrial Neoplasms and Carcinoma, Ovarian Epithelial. Regeneron Pharmaceuticals sponsors the most, 2. Open Payments lists research payments to Dr. Bouberhan that name 2 trials.

CMS Open Payments shows 3 general payments to Dr. Bouberhan from 3 drug and device companies in 2025. Education make up the largest share, 62% of the total. AstraZeneca Pharmaceuticals LP paid the most, $43. It also lists 19 research payments totaling $4,335 from 2022 to 2025, naming 2 clinical trials.

Dr. Bouberhan graduated from University of Virginia School of Medicine in 2012.